Compare ASB & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASB | ICUI |
|---|---|---|
| Founded | 1861 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.9B |
| IPO Year | N/A | 1995 |
| Metric | ASB | ICUI |
|---|---|---|
| Price | $26.37 | $142.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $28.82 | ★ $182.25 |
| AVG Volume (30 Days) | ★ 2.0M | 270.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $19.08 | N/A |
| Revenue Next Year | $7.73 | $4.10 |
| P/E Ratio | ★ $10.23 | $4,754.33 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.32 | $107.02 |
| 52 Week High | $29.52 | $160.29 |
| Indicator | ASB | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 41.51 | 40.25 |
| Support Level | $25.29 | $142.11 |
| Resistance Level | $27.69 | $151.64 |
| Average True Range (ATR) | 0.86 | 6.62 |
| MACD | -0.27 | -1.01 |
| Stochastic Oscillator | 30.43 | 18.31 |
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.